Bladder Cancer Clinical Trial
Official title:
Phase 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer
The goal of this part (Part 1) of this clinical research study is to learn about the safety of giving 2 doses of SCH 72105 (also known as rAd-IFN) directly into the bladder to patients with bladder cancer that has come back. The goal of Part 2 of this study is to learn about the safety of giving 2 more doses of SCH 72105 directly into the bladder of Part 1 participants who had no sign of bladder cancer after Week 12. The level of effectiveness of SCH 72105 will also be studied by measuring the interferon (IFN) levels in the urine.
The Study Drug:
SCH 72105 is designed to cause "gene transfer" by giving a gene called interferon -alpha-2b
into the body. SCH 72105 is made after being processed in the lab with a study drug called
Syn3. This combination of study drugs is also called SCH 721015 with Syn3. Syn3 is designed
to help the body make a protein called interferon -alpha-2b, and this may help the body's
immune system to react against the cancer.
Study Drug Administration:
On Days 1 and 4, SCH 72105 will be given into your bladder over about 1 minute through a
urinary catheter. A urinary catheter is a thin flexible tube placed through the urinary tube
and into the bladder. SCH 72105 will stay in the bladder for about 1 hour. You will be asked
to turn from left to right, back to stomach, every 15 minutes to allow the bladder surface
to be exposed to the drug.
A belladonna and opium (B&O) suppository will be inserted into your rectum about 30 minutes
before the study drug doses. Levsin SL (hyoscyamine sulfate) will be given by mouth about 15
minutes before the study drug doses. These drugs are used to lower the risk of urinary
urgency (a strong need to urinate).
Study Visits:
On Day 1:
- Blood (about 3 teaspoons) will be drawn for routine tests.
- Urine will be collected to test for IFN levels and to check for infection.
- Your vital signs will be measured before and after the study drug dose.
- You will be asked about any side effects and urinary symptoms you may have had and any
drugs you may be taking.
- Your performance status will be recorded.
On Days 2 and 3 and on Days 5-14:
- Urine will be collected for biomarker testing. Biomarkers in your urine may be related
to your reaction to the study drug.
- Your performance status will be recorded.
- You will be asked about any side effects and urinary symptoms you may have had and any
drugs you may be taking.
On Day 4:
- Blood (about 3 teaspoons) will be drawn for routine tests.
- Urine will be collected for biomarker testing and to check for infection.
- Your vital signs will be measured before and after the study drug dose.
- You will be asked about any side effects and urinary symptoms you may have had and any
drugs you may be taking.
- Your performance status will be recorded.
During Days 1-11, you will add about 1/2 cup of bleach to the toilet bowl before every time
you urinate. You will then wait 15 minutes before flushing. You should avoid public
bathrooms on these days. This procedure is required to avoid exposing other people to the
study drug.
One (1) time a week during Weeks 2-11, the study staff will call and ask you about any side
effects and urinary symptoms you may have had and any drugs you may be taking. During these
calls, your performance status will also be recorded.
At Week 12:
- You will have a physical exam.
- Blood (about 3 teaspoons) will be drawn for routine tests.
- Urine will be collected for biomarker testing and to check for infection.
- Your vital signs will be measured.
- You will have an ECG. This ECG will be used as a screening test to help the doctor
decide if you are eligible to take part in Part 2 of the study.
- Your performance status will be recorded.
- You will be asked about any side effects and urinary symptoms you may have had and any
drugs you may be taking.
- You will have a cystoscopy with biopsies to check the status of the disease. All areas
that the doctor thinks might have a tumor will be biopsied. Your bladder will also be
measured during this procedure.
Length of Participation:
You may receive the 2 doses of the study drug as planned, if the doctor thinks it is in your
best interest. You will not be able to receive the second dose of the study drug if the
disease gets worse or intolerable side effects occur.
Part 2 of the Study:
If the disease has completely responded by Week 12 (no sign of cancer), you will be asked to
take part in Part 2 of this study. In Part 2, participants will receive another 2 doses of
the study drug. There is a separate informed consent form that describes Part 2, including
screening tests that will help the doctor decide if you are eligible. You will be asked to
sign the informed consent form if you agree to take part.
The level of effectiveness of SCH72105 treatment will be studied by measurement of IFN
levels in the daily urine collections.
End-of-Study Visit:
You may choose to stop your study participation at any time. If you choose to stop before
the Week 12 visit, you will be asked to return for an end-of-study visit. You will also be
called by the study staff to ask about your health 1 time a year for the next 2 years. The
following tests and procedures will be performed at the end-of-study visit:
- You will have a physical exam.
- You will have an ECG.
- Urine will be collected for routine tests.
Follow-Up:
If you had any signs of bladder cancer at Week 12, the study staff will call you at Months
6, 9, 12, 24, and 36. You will be asked if you have had any serious side effects.
This is an investigational study. SCH 72105 is not FDA approved or commercially available.
It is currently being used for research purposes only.
Up to 9 patients will take part in this study (9 total, for Parts 1 and 2). All will be
enrolled at MD Anderson.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |